Consultation Meeting with the Stakeholders to Develop M&E Framework for AMR Surveillance
As part of its continued commitment to combat antimicrobial resistance (AMR), Bangladesh has taken a significant step forward in strengthening its national AMR surveillance system through the consulta ...
Gulf CDC Visits IVI to Explore Collaboration with EPIC and AMR Departments
The Gulf Center for Disease Control and Prevention (Gulf CDC) recently visited the International Vaccine Institute (IVI) and engaged in a productive discussion with the Epidemiology, Public Health, Im ...
🌍 Advanced Antimicrobial Resistance (AMR) Data Analysis and Clinical Leadership Training in Seoul 📊
We were honored to organize and host a transformative three-day Advanced Antimicrobial Resistance (AMR) Data Analysis and Clinical Leadership Training at the Grand Intercontinental Hotel, Seoul. This ...
Bangladesh Country Report – CAPTURA I
CAPTURA is a Fleming Fund, UK Aid initiative, led by the International Vaccine Institute (IVI) to increase the volume of quality data on antimicrobial resistance (AMR), consumption (AMC), and use (AMU ...
CAPTURA Findings Dissemination in Nepal
Lorem ipsum dolor sit amet, consectetur adipisc glelit, sed do eiusmod tempor incididunt .ut labo et dolore magna aliqua.
IVI and the Government of Bangladesh join forces to boost AMR response in South Asia
Lorem ipsum dolor sit amet, consectetur adipisc glelit, sed do eiusmod tempor incididunt .ut labo et dolore magna aliqua.
EVIDENCE TO ACTION: Advancing the Antimicrobial Resistance Agenda During a Pandemic
Lorem ipsum dolor sit amet, consectetur adipisc glelit, sed do eiusmod tempor incididunt .ut labo et dolore magna aliqua.
IVI-led CAPTURA consortium releases first country report on AMR data in Bangladesh
Lorem ipsum dolor sit amet, consectetur adipisc glelit, sed do eiusmod tempor incididunt .ut labo et dolore magna aliqua.
Fleming Fund Regional Workshop in Seoul, South Korea
Lorem ipsum dolor sit amet, consectetur adipisc glelit, sed do eiusmod tempor incididunt .ut labo et dolore magna aliqua.